Skip to content

Humanigen (HGEN) Shares Plunge After FDA Declines EUA Request

Sam Boughedda trader
Updated 9 Sep 2021

Humanigen (NASDAQ: HGEN) shares have plunged over 50% premarket after the FDA declined its request for emergency use authorization of lenzilumab to treat newly hospitalized COVID-19 patients.

According to Humanigen, the FDA stated in its letter that it could not conclude that the known and potential benefits of lenzilumab outweigh the known and potential risks of its use as a treatment for COVID-19.

The company said the FDA has committed to working with Humanigen to develop lenzilumab and has invited it to submit additional data as it becomes available.

“We remain committed to bringing lenzilumab to patients hospitalized with COVID-19,” said Cameron Durrant, CEO of Humanigen.

“We believe the ongoing ACTIV-5/BET-B trial, which has been advanced to enroll up to 500 patients, may provide additional safety and efficacy data sufficient to support our efforts to obtain an EUA to treat hospitalized COVID-19 patients.”

Humanigen shares are trading at $6.96 premarket, down 53.94%. Its stock price is down 13.66% so far this year.

Should You Invest in Humanigen Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples.